Moricizine (Hydrochloride)
Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1].
Product Specifications
CAS Number
[29560-58-5]
Product Name Alternative
EN 313; Ethmozin; Moracizine
UNSPSC
12352005
Hazard Statement
H302
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/moricizine-hydrochloride.html
Purity
98.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OCC)NC(C=C1N2C(CCN3CCOCC3)=O)=CC=C1SC4=C2C=CC=C4.[H]Cl
Molecular Formula
C22H26ClN3O4S
Molecular Weight
463.98
Precautions
H302
References & Citations
[1]Bigger JT Jr. Cardiac electrophysiologic effects of moricizine hydrochloride. Am J Cardiol. 1990 Feb 20;65 (8) :15D-20D; discussion 68D-71D.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Silicibacter pomeroyi Phospho-N-acetylmuramoyl-pentapeptide-transferase (mraY), partial
SMYD1, CT (SMYD1, SET and MYND domain-containing protein 1) (Biotin) discontinued